Trails Edge Capital Partners, LP — 13F Holdings & Portfolio
CIK 2077247 · latest 13F-HR filed 2026-08-14
Trails Edge Capital Partners, LP manages $629.9M in 13F-reported U.S. long-equity assets across 35 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are LBRX (7.85%), NRIX (6.06%), IMCR (5.36%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 13 new positions and exited 4; 14 existing positions rose in reported value and 5 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
3 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 50.3%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Apr 14, 2026.
SUITE 900
ATLANTA, GA 30326
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| DIAZ, MATTHEW, JAMES Control | CHIEF FINANCIAL OFFICER, CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER since Jan 2025 | Less than 5% | Individual |
| TRAILS EDGE CAPITAL PARTNERS, LLC Control | GENERAL PARTNER since Oct 2024 | Less than 5% | Domestic Entity |
| YEHUDAI, ORTAV, DANIEL Control | PRINCIPAL since Oct 2024 | 75% or more | Individual |
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- DESIGN THERAPEUTICS INC$19.9M +219.4%
- 4D MOLECULAR THERAPEUTICS IN$17.5M +144.3%
- LB PHARMACEUTICALS INC$16.9M +51.9%
- IMMUNOCORE HLDGS PLC$13.2M +64.0%
- NURIX THERAPEUTICS INC$11.1M +41.3%
Top Trims
- INVENTIVA SA-$4.7M -31.9%
- MIRUM PHARMACEUTICALS INC-$4.6M -15.1%
- VTV THERAPEUTICS INC-$2.3M -42.1%
- REVOLUTION MEDICINES INC-$2.1M -9.0%
- MINERVA NEUROSCIENCES INC-$674.0K -7.9%
New Positions
- FIRST TRACKS BIOTHERAPEUTICS$30.5M
- BIOMARIN PHARMACEUTICAL INC$29.3M
- INSMED INC$24.6M
- KAILERA THERAPEUTICS INC$21.7M
- INCYTE CORP$17.6M
Exited Positions
- VAXCYTE INC$38.5M
- DEFINIUM THERAPEUTICS INC$32.9M
- ARCUS BIOSCIENCES INC$22.6M
- IMMUNOVANT INC$10.3M
Trails Edge Capital Partners, LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $49.4M | 7.85% | 1,523,022 | SH |
| 2 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $38.2M | 6.06% | 1,573,220 | SH |
| 3 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $33.8M | 5.36% | 1,063,234 | SH |
| 4 | FIRST TRACKS BIOTHERAPEUTICS | TRAX | 337185102 | $30.5M | 4.84% | 1,514,000 | SH |
| 5 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 35104E100 | $29.6M | 4.70% | 2,227,917 | SH |
| 6 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $29.3M | 4.65% | 512,000 | SH |
| 7 | DESIGN THERAPEUTICS INC | DSGN | 25056L103 | $29.0M | 4.60% | 2,001,282 | SH |
| 8 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $26.6M | 4.22% | 440,000 | SH |
| 9 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $26.1M | 4.15% | 223,312 | SH |
| 10 | INSMED INC | INSM | 457669307 | $24.6M | 3.90% | 230,331 | SH |
| 11 | CYTOKINETICS INC | CYTK | 23282W605 | $24.5M | 3.90% | 288,089 | SH |
| 12 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $24.3M | 3.85% | 1,110,000 | SH |
| 13 | NEUROGENE INC | NGNE | 64135M105 | $22.5M | 3.57% | 714,885 | SH |
| 14 | KAILERA THERAPEUTICS INC | KLRA | 482931102 | $21.7M | 3.44% | 984,786 | SH |
| 15 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $21.7M | 3.44% | 115,750 | SH |
| 16 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $18.4M | 2.92% | 9,051,318 | SH |
| 17 | INCYTE CORP | INCY | 45337C102 | $17.6M | 2.79% | 155,000 | SH |
| 18 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $16.5M | 2.62% | 891,881 | SH |
| 19 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $14.6M | 2.32% | 750,000 | SH |
| 20 | FAETH THERAPEUTICS INC | FTH | 81728A207 | $12.9M | 2.05% | 515,335 | SH |
| 21 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $12.0M | 1.91% | 2,571,478 | SH |
| 22 | OPUS GENETICS INC | IRD | 67577R102 | $11.3M | 1.79% | 2,743,658 | SH |
| 23 | SOL-GEL TECHNOLOGIES LTD | SLGL | M8694L137 | $10.3M | 1.64% | 139,445 | SH |
| 24 | AURA BIOSCIENCES INC | AURA | 05153U107 | $10.2M | 1.63% | 1,443,333 | SH |
| 25 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $10.1M | 1.61% | 4,134,969 | SH |
| 26 | INVENTIVA SA | IVA | 46124U107 | $10.0M | 1.60% | 2,657,997 | SH |
| 27 | CAMP4 THERAPEUTICS CORP | CAMP | 13463J101 | $8.4M | 1.34% | 1,932,937 | SH |
| 28 | ALTIMMUNE INC | ALT | 02155H200 | $8.1M | 1.28% | 2,660,000 | SH |
| 29 | MINERVA NEUROSCIENCES INC | NERV | 603380205 | $7.9M | 1.25% | 1,419,000 | SH |
| 30 | PROMIS NEUROSCIENCES INC | PMN | 74346M505 | $7.3M | 1.16% | 557,103 | SH |
| 31 | ONKURE THERAPEUTICS INC | OKUR | 68277Q105 | $6.6M | 1.04% | 1,438,456 | SH |
| 32 | FORTE BIOSCIENCES INC | FBRX | 34962G208 | $5.8M | 0.92% | 273,181 | SH |
| 33 | RESEARCH ALLIANCE CORP III | RACC | G75226103 | $5.3M | 0.85% | 500,000 | SH |
| 34 | VTV THERAPEUTICS INC | VTVT | 918385204 | $3.2M | 0.51% | 85,192 | SH |
| 35 | IMAGENEBIO INC | IMA | 45175G207 | $1.7M | 0.26% | 282,004 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $629.9M | 35 | 0002077247-26-000004 |
| 2026-03-31 | 2026-05-15 | $436.5M | 27 | 0002077247-26-000003 |
| 2025-12-31 | 2026-02-17 | $404.7M | 23 | 0002077247-26-000002 |
ATLANTA, GA 30326